Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22327276 | 1.00 | KDM4E (0.47) | KDM4EPOLA1POLBHPGDPNP | |
| SCHEMBL26156306 | 0.86 | KDM4E (0.49) | KDM4EPOLA1POLBHPGDPNP | |
| SCHEMBL22327279 | 0.85 | KDM4E (0.35) | KDM4EPOLA1POLB | |
| SCHEMBL22327282 | 0.85 | KDM4E (0.35) | KDM4EPOLA1POLB | |
| SCHEMBL26156310 | 0.84 | KDM4E (0.51) | KDM4EPOLA1POLBHPGDPNP | |
| SCHEMBL26068426 | 0.84 | HIF1A (0.42) | KDM4ETP53SMN1; SMN2HIF1A | |
| SCHEMBL22327401 | 0.84 | HIF1A (0.42) | KDM4ETP53SMN1; SMN2HIF1A | |
| SCHEMBL22327403 | 0.84 | HIF1A (0.42) | KDM4ETP53SMN1; SMN2HIF1A | |
| SCHEMBL26068425 | 0.84 | HIF1A (0.42) | KDM4ETP53SMN1; SMN2HIF1A | |
| SCHEMBL24971055 | 0.84 | KDM4E (0.32) | KDM4EPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | LG ELECTRONICS INC. (KR) | 2022-04-28 | — | — | US | disclosed |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2020-10-29 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200340051-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | KDM4E 3403/4885POLA1 102/4885POLB 24/4885 |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | KDM4E 3403/4885POLA1 102/4885POLB 24/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | KDM4E 4194/4885POLA1 37/4885POLB 2/4885 |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | NUDT21, CPSF7, DCLRE1A | KDM4E 3403/4885POLA1 102/4885POLB 24/4885 |
| US-10738072-B1 | Nucleotide analogues | NUDT1, POLN, TYMP | KDM4E 3976/4885POLA1 61/4885POLB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.